Sanofi American Depositary Receipt (SNY)
SNY & REGN's Dupixent Wins FDA Nod for Pediatric Use in Urticaria
Sanofi wins FDA nod to expand Dupixent in kids aged 2-11 years, marking the first biologic for young patients with uncontrolled CSU.
SNY's Tzield Gets FDA Nod for Kids, Sarclisa SC BLA Faces Delay
Sanofi wins FDA nod to expand Tzield's use to younger patients, while Sarclisa SC review faces delay with a new decision date set for July 2026.
Sanofi Tops Q1 Earnings Estimates as Dupixent & New Drugs Drive Growth
Sanofi beats Q1 estimates as Dupixent and new drugs fuel double-digit growth, with strong sales and earnings gains supporting its 2026 outlook.
Sanofi Posts Higher Sales Amid Leadership Transition
Sales rose 14% to €10.51 billion at constant currency, boosted by new launches and recent acquisitions.
Sanofi's first quarter earnings edges past estimates ahead of CEO change
French drugmaker Sanofi on Thursday reported first-quarter profit and revenue above market expectations, boosted by resilient demand for its blockbuster asthma and eczema drug Dupixent.
What To Expect From Sanofi In Q1 2026
On April 23, Sanofi will report its results for the first quarter of 2026. As a reminder, its revenue grew 23.1% year-over-year to $13.53 billion in Q4 last year. Meanwhile, Sanofi's non-GAAP P/E ratio [FWD] is 9.66x, which, in my view, clearly indicates that it is trading at a discount.
SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria
Sanofi wins EC nod to expand Dupixent use to children aged 2 to 11 years with CSU, backed by phase III data, marking the first targeted option in the EU.
SNY's Lunsekimig Succeeds in Asthma & CRSwNP Studies, Fails in Eczema
Sanofi posts strong mid-stage results for lunsekimig in asthma and CRSwNP but a setback in atopic dermatitis clouds the broader clinical picture.
Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease
SNY secures EU conditional approval for Rezurock to treat chronic GVHD in adults and children aged 12 years and older.
Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment
Kali Therapeutics said on Monday it has entered into a licensing agreement with French drugmaker Sanofi to develop the privately held firm's experimental treatment for several autoimmune diseases.
Callodine Capital Management LP Purchases 182,837 Shares of Sanofi $SNY
Callodine Capital Management LP grew its stake in Sanofi (NASDAQ: SNY) by 35.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 698,046 shares of the company's stock after acquiring an additional 182,837 shares during the period. Sanofi accounts for
Need Growing EPS And Dividends? Prescribe Sanofi
Sanofi is deeply undervalued, trading at a 29% discount to a $65 fair value estimate, with a forward P/E of 9.2 versus a 10-year average of 13. Robust growth is driven by blockbuster drugs like Dupixent and a strong pipeline, supporting consensus EPS growth of 9.3% annually through 2028. SNY offers a 5.1% dividend yield, backed by 31 consecutive annual increases and a sustainable payout ratio in the high-40% range.
